Silexion Therapeutics Corp — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
On October 26, 2026, Silexion shareholders approved an ordinary resolution increasing authorized share capital from US$2.1M (15.9M shares at $0.135 par) to US$69.6M (515.9M shares at $0.135 par). This creates 500M new ordinary shares of par value US$0.135 each. No issuance occurred; only authorization granted.
Why this rating
Massive authorization relative to tiny $4.2M asset base signals dilution risk; unclear if shares issued yet. Material potential, not imminent certainty.
Price action (we called it neutral)
before filing · preread $0.01 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.